DENVER, May 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, May 14, 2025, and host a webcast and conference call to discuss its financial results and business progress. A replay of the call will be available after 7:30 pm ET ...

Core Insights - SeaStar Medical Holding Corporation is focused on transforming treatments for critically ill patients facing organ failure and potential loss of life [3] - The company’s first commercial product, QUELIMMUNE (SCD-PED), received FDA approval in 2024 for treating life-threatening acute kidney injury (AKI) due to sepsis in critically ill pediatric patients [3] - SeaStar's Selective Cytopheretic Device (SCD) therapy has been granted Breakthrough Device Designation by the FDA for four therapeutic indications, which may facilitate faster approval and better reimbursement dynamics [3] - The company is conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a condition affecting over 200,000 adults in the U.S. annually [3] Event Information - Eric Schlorff, CEO of SeaStar Medical, will be featured on the Benzinga All Access Show on April 30, 2025, at approximately 10:50 am Eastern Time [1] - The event will be broadcast live and available for later viewing on SeaStar Medical's investor relations website [2]